Loading data for NRSNW — first visit, this takes a few seconds.
NeuroSense Therapeutics L... (NRSNW)
NasdaqCM: NRSNW
· Echtzeitkurs · USD
0.05
-0.02 (-28.57%)
Zum Schluss: Aug 18, 2026, 3:19 PM
NeuroSense Therapeutics Ltd. (NRSNW) Stock Price, Analysis & Data
-28.57% (1D)
| Geld | n/a |
| Marktkapitalisierung | n/a |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -11.13 Mio |
| Beta | 1.60 |
| EPS (ttm) | -0.94 |
| KGV (TTM) | n/a |
| Forward-KGV | n/a |
| KBV (TTM) | -1.04 |
| KUV (TTM) | n/a |
| Earnings Date | n/a |
| Brief | n/a |
| Volumen | 3,411 |
| Ø Vol. (20D) | |
| Eröffnung | 0.30 |
| Vortagesschluss | 0.07 |
| Tagesspanne | 0.05 - 0.06 |
| 52-Wk Range | 0.05 - 0.06 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über NRSNW
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and ...
IPO Datum Jul 17, 2026
Mitarbeiter 17
Börse NasdaqCM
Tickersymbol NRSNW
Website https://www.neurosense-tx.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von NeuroSense Therapeutics 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -11.13 Mio, ein Anstieg von 8.96 %.
Finanzberichte